

Contents

Part I History and Epidemiology

1 History of Multiple Myeloma	3
Robert A. Kyle and David P. Steensma	
1.1 Ancient Origins	4
1.1.1 Early Well-Documented Cases.....	4
1.2 Henry Bence Jones (1813–1873)	7
1.3 Other Contributions to Bence Jones Proteinuria	10
1.4 Other Early Cases of Multiple Myeloma	11
1.4.1 The Case of Dr. Loos	11
1.4.2 The First Myeloma Case in America	12
1.4.3 Recognition of the Poor Prognosis Associated with Bence Jones Protein	13
1.4.4 Case Series	13
1.4.5 Plasma Cells	13
1.4.6 Antibodies	14
1.4.7 Electrophoresis	14
1.4.8 Monoclonal Versus Polyclonal Gammopathies	15
1.5 Alkylator and Corticosteroid-Based Therapy	15
1.5.1 Urethane	15
1.5.2 Melphalan	16
1.5.3 Prednisone	16
1.5.4 Alkylator Combinations	16
1.6 Stem Cell Transplantation	17
1.6.1 Novel Agents	17
References	19

2 Epidemiology of Multiple Myeloma	25
Nikolaus Becker	
2.1 Descriptive Epidemiology.....	26
2.2 Etiology.....	26
2.2.1 Tobacco.....	26
2.2.2 Alcohol.....	29
2.2.3 Diet.....	29
2.2.4 Obesity.....	29
2.2.5 Physical Activity.....	30
2.2.6 Hormonal Factors.....	30
2.2.7 Environment and Occupation.....	30
2.2.8 Ionizing Radiation.....	30
2.2.9 Inheritance.....	31
2.2.10 Medical History, Viruses, Immunological Conditions.....	31
2.3 Summary.....	31
 Part II Pathophysiology	
 3 Molecular Pathogenesis of Multiple Myeloma:	
Chromosomal Aberrations, Changes in Gene Expression,	
Cytokine Networks, and the Bone Marrow Microenvironment	39
Bernard Klein, Anja Seckinger, Thomas Moehler, and Dirk Hose	
3.1 Survival, Growth, and Inhibitory Factors of Normal Plasma Cells.....	40
3.1.1 Survival and Growth Factors of Normal Plasma Cells and Their Generation.....	40
3.1.2 Inhibitory Factors Expressed by Normal Plasma Cells.....	43
3.2 Chromosomal Aberrations.....	44
3.2.1 Background and Methods.....	44
3.2.2 Types of Chromosomal Aberrations.....	46
3.2.3 Association of Chromosomal Aberrations.....	47
3.2.4 Clonal, Subclonal, and Progression-Related Aberrations and Chromosomal Instability.....	47
3.2.5 Prognostic Relevance of Chromosomal Aberrations.....	48
3.3 Changes in Gene Expression in Multiple Myeloma.....	50
3.3.1 Gene Expression–Based Classifications in Myeloma.....	50
3.3.2 Gene Expression and Risk Stratification.....	51
3.4 Proliferation and Cell Cycle Regulation.....	52
3.4.1 “Potential to Proliferate” of Normal Plasma Cells.....	52
3.4.2 D-Type Cyclin Expression in Myeloma.....	53
3.4.3 Proliferation of Malignant Plasma Cells.....	53
3.5 Myeloma Cell Survival and Proliferation Factors.....	54

3.5.1	Interferon Alpha/Interleukin-6 Family and Activation of the JAK/STAT and MAP Kinase Pathways	55
3.5.2	Factors Activating the PI-3 and MAP Kinase Pathways: Insulin-Like Growth Factor 1, Heparin-Binding Growth Factors	56
3.5.3	Heparin-Binding Factors	58
3.5.4	Factors Activating NF-Kappa B: BAFF Family	59
3.5.5	Hierarchy of Myeloma Cell Growth Factors and Potential Clinical Applications.....	59
3.6	Multiple Myeloma Cells and the Microenvironment.....	60
3.6.1	Pathogenesis of Myeloma-Induced Bone Disease	61
3.6.2	Patterns and Healing of Bone Defects.....	63
3.6.3	Therapeutic Strategies for Treatment and Prevention of Myeloma Bone Disease	64
3.7	Pathogenetic Model of Multiple Myeloma	64
3.7.1	Disease Activity, Tumor Load, and Molecular Characteristics of Myeloma Cells	67
3.7.2	Multistep Transformation of Myeloma Cell Model	69
3.7.3	Transformation of Bone Marrow Microenvironment Model	70
4	Angiogenesis and Vasculogenesis in Multiple Myeloma: Role of Inflammatory Cells.....	87
	Angelo Vacca and Domenico Ribatti	
4.1	Introduction	87
4.2	Angiogenesis and Antiangiogenesis in Multiple Myeloma	88
4.3	The Role of Inflammatory Cells in Tumor Angiogenesis	89
4.4	The Involvement of Macrophages in Vascular Mimicry in MM.....	90
4.5	The Involvement of Mast Cells in Vascular Mimicry in MM.....	91
4.6	Vasculogenesis by Hematopoietic Stem and Progenitor Cells.....	92
4.7	Concluding Remarks	93
5	Immunology and Immunotherapeutic Approaches in Multiple Myeloma	97
	Christoph Schlude and Philipp Beckhove	
5.1	Introduction	97
5.2	Myeloma-Associated Antigens	98
5.3	Vaccination	99
5.4	Immune Evasion.....	101
5.5	Regulatory T Cells.....	102
5.6	Humoral Immunotherapy	102
5.7	Adoptive Cellular Therapy	103
5.8	Conclusion.....	104

Part III Clinical Features

6 Monoclonal Gammopathy and Smoldering Multiple Myeloma: Diagnosis, Staging, Prognosis, Management	113
Jens Hillengass, Thomas Moehler, and Michael Hundemer	
6.1 Definition of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (sMM)	114
6.2 Prevalence of MGUS	114
6.3 Differential Diagnosis and Diagnostic Assessment	116
6.3.1 Initial Diagnostic Assessment	116
6.3.2 Follow-up Recommendations	117
6.4 Risk Factors for Progression	118
6.4.1 Prognostic Factors for Progression for Patients with MGUS	118
6.4.2 Prognostic Factors for Progression of sMM	119
6.4.3 Genetic Risk Stratification	122
6.5 Etiology and Pathogenesis of MGUS and sMM and Considerations Regarding Primary Prevention	122
6.5.1 Population-Based Studies	122
6.5.2 Concept of Chronic Antigenic Stimulation	122
6.5.3 Molecular Genetics and Cytogenetics	123
6.5.4 Concepts for Secondary Prevention of Progression to Multiple Myeloma and Other Lymphoproliferative Diseases	124
6.5.5 Summary of Clinical Studies to Halt Progression	124
6.6 Summary and Conclusions	126
7 Imaging in Multiple Myeloma	133
Stefan Delorme and Andrea Baur-Melnyk	
7.1 Introduction	133
7.2 Imaging Methods	134
7.2.1 Morphologic Imaging	134
7.2.2 Functional Imaging	135
7.3 Radiological–Pathological Correlation	136
7.4 Differential Diagnosis	142
7.5 Staging	143
7.6 Treatment Effects	144
7.7 Prognostic Factors	144
7.8 The Radiologist's Tasks	145

Part IV Therapy

8 Novel Drugs in Myeloma: Harnessing Tumour Biology to Treat Myeloma	151
Kevin Boyd, Faith E. Davies, and Gareth J. Morgan	
8.1 Introduction	151
8.2 Intracellular Drug Targets	152

8.2.1	Targeting Signalling Pathways Within Myeloma Cells	152
8.2.2	Targeting the Unfolded Protein Response.....	158
8.2.3	Targeting Chromatin.....	159
8.2.4	Targeting Intracellular Cell Cycle Regulatory Proteins	162
8.3	Extracellular Drug Targets	163
8.3.1	Targeting Cytokines or Their Receptors.....	163
8.3.2	Targeting Myeloma Cell Adhesion Molecules.....	167
8.3.3	Targeting the Host Immune System	169
8.3.4	Targeting Bone Disease.....	171
8.4	Conclusion.....	173
9	Firstline Treatment and Maintenance in Newly Diagnosed Multiple Myeloma Patients	189
	Murielle Roussel, Thierry Facon, Philippe Moreau, Jean-Luc Harousseau, and Michel Attal	
9.1	Frontline Treatment in MM Patients Eligible for High-Dose Therapy	190
9.1.1	Induction Treatment: What Combination of New Drugs?	190
9.1.2	Autologous Stem Cell Transplantation Upfront or at the Time of Relapse?.....	194
9.1.3	Maintenance/Consolidation Treatment	195
9.2	Frontline Treatment in Elderly MM Patients	196
9.2.1	What Is the Best Combination with Alkylating Agents?	197
9.2.2	Firstline Treatment: Can New Agents Replace Alkylators?	200
9.2.3	Can We Reduce Toxicities of New Drugs-Incorporating Regimens?	201
9.2.4	Maintenance Therapy in Elderly	202
10	High-Dose Therapy and Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma.....	207
	Rainer Haas, Ingmar Bruns, Guido Kobbe, and Roland Fenk	
10.1	Introduction	208
10.2	Peripheral Blood Stem Cell Mobilization	208
10.2.1	The Role of Adhesion Molecules.....	208
10.2.2	The Role of Hematopoietic Growth Factors	210
10.2.3	The Role of Cytotoxic Stem Cell Mobilization.....	212
10.2.4	The Role of Pegfilgrastim for Stem Cell Mobilization	213
10.3	High-Dose Therapy and Autologous Stem Cell Transplantation.....	215
10.3.1	The Beginning of High-Dose Therapy in the 1980	215
10.3.2	The Role of Purging of the Autograft	216
10.3.3	The Role of the Conditioning Regimen	217
10.3.4	Supportive Care During High-Dose Chemotherapy	218
10.3.5	High-Dose Chemotherapy Is Superior to Conventional Chemotherapy.....	219
10.3.6	Timing of High-Dose Chemotherapy	221
10.3.7	Tandem Autologous Transplantation	221

10.3.8 The Role of Induction Treatment	222
10.3.9 The Role of Consolidation or Maintenance Treatment	223
10.3.10 Prognostic Factors	224
10.3.11 Targeted Versus High-Dose Chemotherapy	226
11 Therapy of Relapsed and Refractory Multiple Myeloma	239
Thomas Moehler and Hartmut Goldschmidt	
11.1 Introduction	240
11.2 Diagnostic Workup of Patients at Relapse	240
11.3 Conventional Treatment of Relapsed/Refractory Disease	240
11.4 High-Dose Chemotherapy (HDCT) Supported by Autologous Stem Cell Transplantation	241
11.5 Allogeneic Stem Cell Transplantation.....	242
11.6 Thalidomide and Immunomodulatory Drugs	245
11.6.1 Thalidomide as Single Agent and Combined with Corticosteroids	245
11.6.2 Thalidomide in Combination with Chemotherapy/Corticosteroids	246
11.6.3 Lenalidomide.....	249
11.6.4 Lenalidomide Combination Therapies	249
11.6.5 Pomalidomide.....	251
11.7 Bortezomib	251
11.7.1 Bortezomib Single Agent.....	251
11.7.2 Bortezomib Combination Therapy	252
11.8 Novel Proteasome Inhibitors.....	254
11.9 Combination of Novel Agents.....	255
11.10 Emerging Therapies and Novel Pathways.....	260
11.11 Prognostic Factors	260
11.12 Therapeutic Strategy for Relapsed/Refractory Myeloma Patients	260
12 Allogeneic Transplantation in Multiple Myeloma	273
Gösta Gahrton	
12.1 Introduction	274
12.2 Myeloablative High Dose Conditioning.....	274
12.3 Molecular Remission.....	275
12.4 Source of Stem Cells	275
12.5 Reduced Intensity conditioning (RIC)	276
12.5.1 Retrospective Studies	276
12.5.2 Prospective Studies.....	276
12.6 How to Improve Results of Allogeneic Transplantation?	279
12.6.1 Donor Lymphocyte Transfusions	279
12.6.2 NK Cells Have Antimyeloma Effect and Moderate GVHD	280
12.6.3 Role of Immunosuppressive Agents in the Conditioning Therapy	280
12.6.4 Targeted Drugs Pretransplant or Posttransplant	281
12.7 Conclusions	281

13 Radiotherapy	285
Sonja Krause, Jürgen Debus, and Dirk Neuhof	
13.1 Solitary Plasmocytoma.....	285
13.1.1 Diagnostic Workup.....	286
13.1.2 Radiotherapy of SBP.....	286
13.1.3 Radiotherapy of EP.....	287
13.1.4 Treatment Toxicity.....	287
13.2 Palliative Treatment of Multiple Myeloma.....	287
13.2.1 Pain Control.....	288
13.2.2 Recalcification.....	288
13.3 Total Body Irradiation (TBI).....	289
14 Osteoplastic Procedures for the Treatment of Vertebral Complications in Multiple Myeloma Patients	293
Christian Kasperk and Ingo Grafe	
14.1 Introduction.....	294
14.2 Osteoplastic Procedures.....	294
14.3 Balloon Kyphoplasty.....	294
14.4 Vertebroplasty.....	295
14.5 Comparison of Kyphoplasty and Vertebroplasty.....	296
14.6 Indications and Contraindications.....	296
14.7 Randomized Controlled Studies of Osteoplastic Procedures for Vertebral Osteoporotic Fractures.....	297
14.8 Studies Using Kyphoplasty and Vertebroplasty in Patients with Multiple Myeloma.....	298
15 Supportive Therapy in Multiple Myeloma	307
Heinz Ludwig and Niklas Zojer	
15.1 Introduction.....	307
15.2 Myeloma Bone Disease.....	308
15.2.1 Mechanisms of Bone Disease.....	308
15.2.2 Bone Fractures.....	309
15.2.3 Vertebral Lesions.....	309
15.2.4 Bisphosphonates.....	309
15.3 Hypercalcemia.....	314
15.3.1 Diagnosis and Symptoms.....	314
15.3.2 Treatment of Hypercalcemia.....	315
15.4 Anemia.....	316
15.4.1 Pathogenesis of Anemia.....	316
15.4.2 Clinical Symptoms of Anemia.....	316
15.4.3 Treatment of Anemia.....	317
15.5 Infections.....	320

15.5.1 Causes of Infections	320
15.5.2 Prophylaxis of Infections.....	321
15.5.3 Vaccination	322
15.5.4 Treatment of Infections	322
15.6 Pain	323
15.6.1 Characteristics and Causes of Pain.....	323
15.6.2 Medical Pain Treatment	324
15.7 Renal Failure	325
15.7.1 Prevalence and Causes of Renal Failure	325
15.7.2 Management of Myeloma-Induced Renal Failure.....	326
Appendix	335